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http://dx.doi.org/10.1016/j.ccr.2013.03.018SUMMARYCancers often relapse after adoptive therapy, even though specific T cells kill cells from the same cancer
efficiently in vitro. We found that tumor eradication by T cells required high affinities of the targeted peptides
for major histocompatibility complex (MHC) class I. Affinities of at least 10 nM were required for relapse-free
regression. Only high-affinity peptide-MHC interactions led to efficient cross-presentation of antigen,
thereby stimulating cognate T cells to secrete cytokines. These findings highlight the importance of targeting
peptides with high affinity for MHC class I when designing T cell-based immunotherapy.INTRODUCTION
Relapse of cancers is very common, even following combinatorial
therapy of surgery, chemotherapy, radiation, and/or immuno-
therapy. For maximal efficacy, drugs depend on reaching the
necessary concentration in the tumormicroenvironment (Skipper,
1986). This critical concentration concept also applies to cellular
effectors, such as neutrophils and T cells (Budhu et al., 2010;
Li et al., 2002, 2004). While cellular effectors or drugs at optimal
concentrations can eradicate all sensitive cancer cells, relapse
may still occur because of the outgrowth of variants. Cancer cells
show extremely high genetic instability, and cancers always
contain variants that are resistant to destruction by a particular
drugor T cell (Anders et al., 2011;Hansonet al., 2000), very similar
to what is found for viruses (Hensley et al., 2009).
For complete eradication, it is important to eliminate every
residual cancer cell, including heritable variants (Singh et al.,
1992; Spiotto et al., 2004; Zhang et al., 2007). However, factors
responsible for T cell elimination of variants have not been deter-
mined. In experiments designed to explore the reason for failed
T cell treatment, we took a reductionist approach, ultimately
directing our focus to the target peptides and, in particular, to
their affinities for major histocompatibility complex (MHC) class
I. We selected several peptides that, when targeted, caused
tumor eradication and others that caused relapse. To reduceSignificance
Cancer relapse remains the greatest obstacle to virtually any ca
peptides for MHC is required for strong stimulation of T cells to
Adoptive T cell transfer therapies should, therefore, target pep
516 Cancer Cell 23, 516–526, April 15, 2013 ª2013 Elsevier Inc.the influence of differences between cancers, we used two
cancer cell lines that were both transduced to express the
different peptides. To reduce differences due to expression
levels, we used the same design of triple peptides fused to fluo-
rescent proteins. Proteasomal cleavage of proteins may not
generate (Chapiro et al., 2006; Popovic et al., 2011) or destroy
immunogenic peptides (Schultz et al., 2002). To minimize differ-
ences in proteasomal cleavage of the fusion proteins, we
designed peptide triplets separated by ‘‘Ala-Ala-Tyr’’ cleavage
sites. We targeted antigens with no known oncogenic activity
to reduce the possibility that the nature of a particular targeted
antigen prevented the cancer from escaping. To exclude the in-
fluence of other T cells helping or regulating the relevant CD8+
T cells, T cell receptor (TCR)-transgenic T cells with a single
specificity were adoptively transferred into hosts, which were
TCR-transgenic for an irrelevant target. Finally, a single adoptive
T cell transfer regimenwas usedwithout providing any additional
stimulation, such as vaccination or administration of cytokine.
RESULTS
Cancer Cells Expressing Different Peptides Are Killed
by T Cells with Similar Efficacy In Vitro
EGFP was fused to minigenes encoding the peptides hen
egg ovalbumin257–264 (OVA257), model peptide SIYRYYGLncer therapy. Our data show that high affinity of the targeted
secrete cytokines and cause relapse-free tumor eradication.
tides that have high affinities for the presenting MHC class I.
Table 1. Abbreviations, Conditions, and Summary of Results for Key Experiments
Target Peptide on Cancer Cells Hosts T Cells
Tumor
RejectionDesignation Sequence MHC
Affinity of Peptide
for MHC (IC50 [nM])
a Designation
Relationship of
Antigen to Recipient Designation
Relationship of
Antigen to Donor
SIY SIYRYYGL Kb 1.1 OT-I nonself 2C nonself 5/5b,c,d,e
none 0/6b
OVA257–264 SIINFEKL 0.9 2C nonself OT-I nonself 4/4
f
none 0/4f
Tyr369–377 FMDGTMSQV A2 4.2
g OTA self FH self 6/7h
none 0/5h
hgp10025–33 KVPRNQDWL
i Db 186 OT-I nonself pmel nonself 1/8c
none 0/2
EGP EGPRNQDWL 454 OT-I nonself pmel nonself 1/6d
none 0/5
mgp10025–33 EGSRNQDWL 22,975 OT-I self pmel self 1/12
e
none 0/6
See Table S1 for details.
aIC50 values represent the geometric mean of five or more experiments.
bp = 0.002.
cp < 0.005.
dp = 0.015.
ep < 0.001.
fp < 0.029.
gA higher IC50 value of 65 nMwas published for this peptide earlier (Colella et al., 2000). The differences in affinity measurements likely arose as a result
of small differences in reagents, methodology, and procedures.
hp = 0.015.
iOnly the underlined amino acids differ between the three gp100 peptide variants.
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Tumor Relapse and Peptide-MHC Affinity(SIY), mouse Tyrosinase369–377 (Tyr369), mouse or human
gp10025–33 (mgp10025 and hgp10025, respectively), and a het-
eroclitic gp10025–33 (EGP); EGP differs from mgp10025 only in
the third amino acid (EGPRNQDWL versus EGSRNQDWL),
while it shares the proline at position 3 with hgp10025
(KVPRNQDWL) (Table 1). A Cerulean fusion gene was gener-
ated only for SIY (Figures 1A and 1C, top). The fibrosarcoma
line MC57 of C57BL/6 origin was used to generate lines
that expressed the fusion genes at high levels (Figure 1B).
Furthermore, the chimeric human leukocyte antigen (HLA)-
A2.1/H-2Db molecule HHD was cotransduced with the Tyr369-
EGFP fusion protein to generate MC57-TyrHHD (Figure 1C,
bottom).
Assays in vitro demonstrated similar killing of the cancer
lines by cognate peptide-activated T cells (Figure 1D). 2C
T cells, whose TCR binds SIY, killed the MC57-SIY line, and
pmel T cells killed MC57 cells expressing mouse gp10025,
human gp10025 or EGP. Interestingly, Tyr369-specific T cells
derived from the FH TCR-transgenic, tyrosinase (Tyr)-deficient
albino mouse (AFH) or Tyr-positive black mouse (FH) killed
MC57-TyrHHD target cells similarly well. Together, the results
imply there is sufficient direct presentation of all processed
peptides and sufficient avidity of the T cells for efficient killing
in vitro.
T Cells Targeting SIY, OVA257, or Tyr369 Eradicate Large
Tumors
SIY-expressing MC57-SIY cells were injected in TCR-transgenic
mice of irrelevant specificity (OT-I). OVA257-transfected cancercells were injected in 2C TCR-transgenic mice; MC57-TyrHHD
cancer cells were grown in OT-I TCR- and AAD-transgenic
mice, which did (OTA) or did not express tyrosinase (albino;
AOTA). In all cases, cancer cells produced progressively growing
tumors within 1 week (Figure 2A). At least 2 weeks after cancer
cell injection, when tumors reached about 500 mm3, mice were
treated with T cells. As published by our laboratory, tumors ex-
pressing SIY and treated with 2C T cells were eradicated (Fig-
ure 2B, upper left; Table 1; Table S1 available online; Spiotto
et al., 2004). Here, we also show that OVA257-expressing tumors
treated with OT-I T cells were rejected (Figure 2B, middle left)
and FH T cells eradicated Tyr-positive tumors (Figure 2B, lower
left). In this last experiment, FH T cells derived from a Tyr-positive
donor were transferred into a Tyr-positive host and eradicated a
Tyr-expressing tumor. Together, this and other experiments
using FH TCR-transgenic T cells from Tyr-negative donors
(AFH) and Tyr-negative (AOTA) or Tyr-positive (OTA) hosts
showed that tumors could be rejected (1) whether the targeted
peptide was self or nonself for the tumor-bearing host and (2)
whether the targeted peptide was self or nonself for the donor
T cells (Figure S2A). This may be unique to our model, since a
different model showed that low ubiquitous expression of a
transgene prevented the rejection of antigen-expressing tumors
through the induction of tolerance (Buschow et al., 2010). Levels
of antigen expression in the host and/or tumor, type of cells that
express the self-antigen, and the source of T cells may likely in-
fluence the outcome. Taken together, targeting any of the three
peptides, SIY, OVA257, or Tyr369, caused eradication of estab-
lished large and solid tumors.Cancer Cell 23, 516–526, April 15, 2013 ª2013 Elsevier Inc. 517
Figure 1. All Transduced Cancer Cell Lines
that Express Antigens at High Levels Were
Effectively Killed In Vitro
(A) Diagram of fusion proteins constructed to
express antigen in MC57 cancer cells. Triple re-
peats of peptide and alanine-alanine-tyrosine (AAY)
proteasomal cleavage sites were fused to fluores-
cent proteins: OVA257, SIY,mouse tyrosinase369-377
(Tyr369), mouse or human gp10025-33 (mgp10025
and hgp10025, respectively), and EGP; a Cerulean
fusion gene was generated only for SIY.
(B) Flow cytometric analysis of peptide-EGFP
fusion proteins expressed by the transducedMC57
fibrosarcoma lines.
(C) MC57-mgp100/SIY expressed mgp10025 and
SIY antigens as EGFP and Cerulean fusion pro-
teins, respectively. The HLA-A2/Db chimeric protein
HHD was cotransduced with the Tyr369-EGFP
fusion protein to generate MC57-TyrHHD. Parental
MC57 (gray) was analyzed for comparison.
(D) Cytolysis of MC57 target cells overexpressing
SIY, mgp10025, hgp10025, EGP, or Tyr369 and HHD
(Tyr) by 2C, pmel, AFH (Tyr-negative), or FH (Tyr-
positive) T cells in a 4.5 hr 51Cr release assay.
Cancer cells expressing noncognate peptide were
used as negative controls. These data are compiled
of three experiments and are representative for
seven independent experiments.
See Figure S1 for induction of vitiligo by FH and
pmel T cells.
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Relapse after Initial Regression Caused by Transferred
T Cells
In contrast, T cells targeting the self-peptide mgp10025 and the
nonself heteroclitic peptides hgp10025 or EGP did not result in
tumor eradication. MC57 lines overexpressing mgp10025,
hgp10025, or EGP were injected into OT-I TCR-transgenic mice
and produced progressively growing tumors within 1 week
(Figure 2A). At least 2 weeks after cancer cell injection, when
the tumors reached about 500 mm3, the mice were treated
with pmel T cells. The tumors regressed initially, but eventually
almost all tumors relapsed (Figure 2B, right panels; Tables 1
and S1).
To exclude any nonantigenic differences in the cancer lines
(caused by transduction and sorting), we used a cell line that ex-
pressed both SIY and mgp10025 antigens (MC57-mgp100/SIY;
Figure 1C). When mice bearing these tumors were treated with
2C or pmel T cells, the outcome was the same as when tumors
from single antigen lines were treated (Figure 2B, upper panels,
red curves). In conclusion, neither human nor mouse gp10025 or
EGP expressed by the cancer cells supported rejection by pmel
T cells.
These findings were not limited to the methylcholanthrene-
induced cancer line MC57 but were confirmed using the
UV-induced cancer line 8101 (Figures S2B and S2D). The518 Cancer Cell 23, 516–526, April 15, 2013 ª2013 Elsevier Inc.line was transduced to overexpress SIY,
human, or mouse gp10025. Again, we
observed eradication of established tu-
mors by adoptive T cell transfer only
when SIY was targeted. Interestingly, inthis model, targeting hgp10025 wasmore effective than targeting
mgp10025; tumors expressing hgp10025 regressed after pmel
transfer, while tumors expressing mgp10025 continued to grow
uninhibitedly.
Treatment of Tumors Expressing Human gp10025 but
Not Murine gp10025 or EGP Results in Outgrowth of
Antigen-Loss Variants
We isolated cancer cells from tumors expressing mgp10025,
hgp10025, or EGP that had relapsed following treatment with
pmel T cells (Figure 2B) and analyzed these for antigen-loss
variants (ALV). All MC57-hgp100 tumors had lost EGFP expres-
sion, which indicated loss of hgp10025, as both were expressed
as a single fusion protein (one representative tumor is shown in
Figure 3). Importantly, the tumor isolated from a nontreated
mouse retained EGFP expression. MC57-mgp100 and MC57-
EGP tumors treated with pmel had also not lost EGFP expres-
sion. All lines expressed mgp100-EGFP or EGP-EGFP at levels
similar to the isolate from a nontreated mouse (Figure 3). These
data suggest that pmel T cells were capable of killing all
hgp10025-expressing MC57 cancer cells but were not capable
of killing all mgp10025- or EGP-expressing cancer cells in the
respective tumors. These findings seem to be influenced also
by the targeted cell, as relapsed tumors formed by 8101-
hgp100 cells mostly retained expression of the antigen (only
Figure 2. Targeting SIY, OVA257, or Tyr369
Eradicated Large Tumors while Targeting
mgp10025, hgp10025, or EGP Caused Initial
Tumor Regression but Was Followed by
Relapse
(A) Cancer cell lines formed progressively growing
tumors within 1 week. TCR-transgenic mice with
irrelevant specificity were challenged subcutane-
ously with 23 106 cancer cells. MC57-SIY, MC57-
mgp100, MC57-mgp100/SIY, MC57-hgp100, and
MC57-EGP were injected into OT-I mice; MC57-
OVA grew in 2C mice and MC57-TyrHHD grew in
AOTA (Tyr-deficient, nonself) and OTA (Tyr-posi-
tive, self). Graphs represent single mice in 11 ex-
periments, listed as nontreated controls in Tables
1 and S1 and Figure S3C.
(B) At least 2 weeks after cancer cell injection,
when tumors reached about 500 mm3, each
mouse was treated once with cognate T cells
(treatment between days 13 and 26, depending on
tumor size, as indicated by the horizontal bars
[┣┫]). Average size of tumors at day of treatment:
2C: 720 mm3, ranging from 448 to 995 mm3; OT-I:
608 mm3, ranging from 440 to 715 mm3; FH:
517 mm3, ranging from 250 to 848 mm3; pmel,
targeting mgp10025: 601mm
3, ranging from 325 to
980 mm3; targeting hgp10025: 470 mm
3, ranging
from 264 to 936 mm3; and targeting EGP:
337 mm3, ranging from 180 to 600 mm3. MC57-
TyrHHD was grown in OTA (self) and treated with
FH T cells (self). The number of rejected tumors per
number of tumors treated is indicated. Data are
derived from 15 independent experiments,
compiled in Tables 1 and S1. *Tumors were iso-
lated and analyzed for antigen expression (see
Figure 3).
See also Figure S2.
Cancer Cell
Tumor Relapse and Peptide-MHC Affinityone of the isolated relapsed tumors was an ALV; data not
shown).
While we did not observe significant differences when
targeting either human or mouse gp10025 in treatments of estab-
lishedMC57 tumors, we did see differences in protection against
cancer cell inoculations. Pmel T cells prevented the outgrowth of
MC57-hgp100 but not of MC57-mgp100 tumors (Figures S3A
and S3C). MC57-mgp100 cells formed tumors in which a large
fraction of cells still expressed the antigen (Figure S3B). Taken
together, pmel T cells showed a stronger effect when targeting
hgp10025 compared to mgp10025 and EGP.
Tumor Eradication Correlates with High Affinity
of Targeted Peptides for MHC
In an effort to understand why targeting some peptides led to
eradication while targeting others resulted in relapse, we first
analyzed the activation status of the T cells transferred to treat
the different tumors. Upon transfer, after peptide stimulation
in vitro, all T cells showed the same CD44hi and CD62Lhi pheno-
type of activated T cells (Figure 4) and demonstrated very similarCancer Cell 23, 516–5killing capabilities in vitro (Figure 1). It is
worth mentioning that before stimulation,
splenocytes from self-reactive TCR-
transgenic mice (pmel and AFH) showedan antigen-experienced phenotype (CD44hi), while T cells from
the nonself, reactive TCR-transgenic 2C mice showed a truly
naive phenotype. However, this difference was overcome after
peptide stimulation in vitro. Interestingly, when isolated from tu-
mors 4 days after adoptive transfer, the T cells that led to erad-
ication of tumors (2C and AFH) showed a more effector-like
phenotype (CD62Llo and CD44hi) compared to the more central
memory-like phenotype (CD62Lhi and CD44hi) found for pmel
T cells. Together, these data suggest that the differences in tu-
mor rejection were not due to differing activation statuses of
the T cells at the time of transfer.
As another variable that could influence the efficacy of tumor
rejection, we analyzed the affinities of the peptides for the pre-
senting MHC molecules. In a cell-free competition-binding
assay, the concentration of inhibitor peptides needed to displace
half of the probe peptide (half maximal peptide displacing
concentration [IC50] in nM) was determined. IC50 values are
reasonable approximations of real KD values (see Experimental
Procedures). A wide range in binding affinities was measured
(Table 1). There was a strong correlation between affinity of the26, April 15, 2013 ª2013 Elsevier Inc. 519
Figure 3. Outgrowth of Antigen-Loss Variants after pmel T Cell
Treatment of Cancer Cells Expressing hgp10025 but Not of Cancers
Expressing mgp10025 or EGP
Cancer cells of relapsed tumors expressing mgp10025, EGP (both gray), or
hgp10025 (black) were isolated after pmel T cell treatment, adapted to culture,
and analyzed for peptide-EGFP fusion gene expression (left panels). MC57
cells (white histogram) cultured in vitro and MC57-mgp100, MC57-EGP (both
gray), or MC57-hgp100 (black) cells isolated from nontreated mice (right
panels) were analyzed as controls. Isolated lines from mgp100- or hgp100-
expressing tumors are representative for four lines each and the isolate from
the EGP-expressing tumor is representative for two lines; all lineswere isolated
after relapse (respective tumors were marked with an asterisk in Figure 2B).
The repeatability in independent experiments strongly suggests that loss of
antigen expression from the hgp10025 cancer cells was not an artifact caused
by adaptation or postisolation culturing.
See also Figure S3.
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Tumor Relapse and Peptide-MHC Affinitypeptide for MHC and tumor eradication. The three target pep-
tides supporting tumor eradication, OVA257, SIY, and Tyr369
displayed strong binding to their cognate MHC (0.9, 1.1, and
4.2 nM, respectively). These high affinities stood in stark contrast
to the affinities we measured for mgp10025, EGP, and hgp10025
(22,975, 454, and 186 nM, respectively). These three peptides
bound the MHC poorly and, when targeted, resulted in relapse
rather than tumor eradication.
Stromal Cells Isolated from Tumors Formed by Cancer
Cells Expressing Peptides with High Affinity to MHC
Stimulate Cognate T Cells Effectively
To analyze why high peptide-MHC affinities were required for
tumor eradication, we performed assays to evaluate the level
of cross-presentation in growing tumors. MC57 and 8101 lines
expressing SIY, mgp10025, or hgp10025 were grown in OT-I520 Cancer Cell 23, 516–526, April 15, 2013 ª2013 Elsevier Inc.TCR-transgenic or Rag1/ mice, respectively; MC57-TyrHHD
was grown in AOTA (nonself) mice. SIY was used as a represen-
tative peptide for the two highest binding peptides OVA257 and
SIY. Enriched populations of CD11b+ stromal cells were ob-
tained from at least 2-week-old untreated tumors and were
compared in their ability to stimulate T cells in vitro to analyze
the level of cross-presentation of the different peptides ex-
pressed by the tumors. For comparison, we used the transduced
MC57 and 8101 cancer lines grown in vitro. As seen for the
similar killing of MC57 cells presenting the different peptides in
Figure 1D, direct presentation also led to comparable amounts
of interferon (IFN)-g and tumor necrosis factor (TNF)-a secretion
by cognate T cells (Figure 5). However, in the 8101 model, more
IFN-g was found when targeting SIY versus hgp10025 and
mgp10025 (Figure S2C). Even bigger differences occurred in
both cancer models when T cells were stimulated with stromal
cells. CD11b+ stromal cells cross-presenting SIY and Tyr369
stimulated cognate T cells even more strongly than directly
presenting cancer cells (Figure 5). In contrast, both gp10025 pep-
tides were very poorly cross-presented. While stromal cells from
hgp10025-expressing tumors stimulated T cells to secrete low
levels of both cytokines, stromal cells from mgp10025 tumors
did not stimulate T cells at all (Figures 5 and S2C). The hetero-
clitic peptide EGP behaved similarly to hgp10025 when cross-
presented; it stimulated pmel T cells to secrete low amounts of
IFN-g (Figure S4). Thus, the peptides with high affinities for
MHC (SIY and Tyr369) were well cross-presented, while peptides
with low affinities (all three gp10025 peptides) were so poorly
cross-presented that the respective stromal cells could not
efficiently stimulate cognate T cells.
Destruction of Tumor Stroma Is StrongerwhenTargeted
Peptides Have High Affinity for MHC
We analyzed regressing MC57 tumors to help us understand
how tumor eradication correlated to peptide-MHC affinities.
Tumors were dissected on day 5 after adoptive T cell transfer,
and we analyzed the viability of CD11b+ stromal cells. Stroma
from tumors expressing SIY or Tyr369 showed a high percentage
of dead cells (Figure 6), a 6- and 5.8-fold increase over back-
ground, respectively. In accordance with the relapse of tumors
from gp10025 peptide-expressing cells, death of tumor stroma
was low, with only 1.9- and 2.2-fold increases over background
for hgp10025 and mgp10025, respectively. In conclusion, tumors
that were eradicated by cognate T cell therapy showed a high
rate of stromal death, while relapsing tumors contained less
dead CD11b+ stromal cells.
DISCUSSION
Our results have a direct impact on the design of adoptive immu-
notherapy. First, andmost importantly, the affinity of the targeted
peptide for the presenting MHC was highly predictable of
success or failure of T cell therapy, indicating that this is a key
variable. Only high-affinity peptides that were efficiently pre-
sented by cancer cells and/or stroma induced cytokine secretion
by T cells, stromal death, and relapse-free regression of tumors.
Second, targeting self-antigens on tumors did not preclude
eradication of large cancers, even though the treated mice
developed vitiligo (data not shown). Such autoimmunity was
Figure 4. T Cells Transferred to Treat the
Tumors Expressing the Different Peptides
Showed the Same Phenotype of Activated
T Cells
T cells of 2C, AFH, and pmel TCR-transgenic mice
were tested for their activation status in ‘‘naive,’’
untreated mice (splenocytes) at day 3 after pep-
tide activation in vitro and on day 4 after adop-
tive transfer (tumor infiltrating cells). Cells were
analyzed by flow cytometry for expression of
CD44 and CD62L and gated on CD8+ T cells ex-
pressing the cognate Vb-chain: Vb8 for 2C, Vb11
for AFH, and Vb13 for pmel. Data are representa-
tive for two or three independent experiments for
the data in vivo and in vitro, respectively.
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et al., 2010; Palmer et al., 2008; Parkhurst et al., 2011; Yee
et al., 2000). As might be expected, we found that the self-pep-
tide with the higher affinity for the presenting MHCmolecule was
associated with stronger autoimmunity (mTyr369 as opposed to
mgp10025). Vitiligo was also detected earlier in mice transgenic
for the FH TCR compared to pmel (Figure S1; Gregg et al., 2010).
We have analyzed the potential of the different peptides to be
cross-presented by tumor stroma. This is an effective readout to
evaluate different affinities of peptides for MHC and more
sensitive than direct presentation by cancer cells. All peptides
were overexpressed by the cancer lines; therefore, no differ-
ences in direct presentation were detected in killing and cytokine
secretion assays, but cross-presentation reflected the results
obtained from the cell-free affinity measurements. Death of
stroma correlated with the amount of cross-presentation and
tumor relapse. Though stromal death seems to be required for
tumor eradication, we do not know whether cross-presentation
is essential. For example, direct T cell stimulation provided by
cancer cells expressing peptides with high affinity for MHC can
lead to strong cytokine production, Fas ligand upregulation,
and bystander killing (Wang et al., 1996), which could destroy
stroma. Stromal cross-presentation may also not be needed
when an essential oncogene on the cancer is targeted (Anders
et al., 2011; Listopad et al., 2013).
Targeted peptides that led to tumor eradication fell into a
category of high-affinity MHC binders (IC50 < 10 nM), whereas
affinities of peptides that led to relapse fell into a category of
intermediate (IC50 between 50 and 500 nM) or low binders
(IC50 > 500 nM). These data are consistent with the low nanomo-
lar affinities needed to provide full protection against lethalCancer Cell 23, 516–5Vaccinia virus infection (Moutaftsi et al.,
2009). Low affinity peptides may allow
perforin-mediated killing, which requires
only two to three peptide/MHC com-
plexes and brief T cell-target cell interac-
tions (Purbhoo et al., 2004). However, the
efficacy of adoptively transferred T cells
to eradicate tumors does not depend on
perforin (Garcia-Hernandez et al., 2010;
Listopad et al., 2013). The high affinity of
peptides for MHC is probably needed
for tumor eradication, because this al-lows the formation of stable synapses between T cells and anti-
gen-positive cancer cells and/or stromal cells cross-presenting
the antigen. At least ten peptide/MHC complexes need to be
engaged for the prolonged interactions required to stimulate
T cells to secrete cytokines (Purbhoo et al., 2004), which are
essential for tumor eradication (Garcia-Hernandez et al., 2010;
Listopad et al., 2013; Zhang et al., 2008). It appears that targeting
peptides with affinities below a certain threshold will result in a
level of stimulation of effector T cells that is insufficient to erad-
icate the cancer, resulting in relapse of antigen-positive or
negative cancer cells.
Several studies have tried to overcome relapse after adoptive
T cell therapy. They show that the antitumor effects of adoptively
transferred T cells can be enhanced by selecting for more
effective T cell populations, multiple transfers of T cells, high-
dose interleukin-2, vaccinations, and/or total body irradiation
(Cheever et al., 1980; Cho et al., 2012; Dummer et al., 2002;
Ho et al., 2003; Ly et al., 2010; Matsui et al., 2003; North,
1982; Overwijk et al., 2003). But even under these conditions,
relapse was often observed when peptides with low affinities
for MHC were targeted (Antony et al., 2005; Gattinoni et al.,
2005, 2009; Overwijk et al., 2003).
TCR affinity can undoubtedly be an important factor
(Gottschalk et al., 2012). However, in the study presented here,
the affinity of the peptides for MHC seemed to determine if
T cells could eradicate tumors or not. As reasons for this, we pro-
pose that the affinities (KD) of the majority of natural TCRs,
measured by surface plasmon resonance, are 1–100 mM (Davis
et al., 1998; Williams et al., 1999). This is a very narrow range,
considering the affinity range from under 1 to more than
20,000 nM measured for the different peptides binding MHC.26, April 15, 2013 ª2013 Elsevier Inc. 521
Figure 5. Only SIY and Tyr369 Are Cross-
Presented, as Detected by Cytokine Secre-
tion by T Cells Stimulated by Stromal Cells
Isolated from Untreated Tumors
CD11b+ stromal cells were isolated from estab-
lished untreated tumors and were cocultured with
peptide-activated T cells. Enriched stromal cells
from tumors grown from MC57-SIY, MC57-
hgp100, and MC57-mgp100 cells (all grown in
OT-I mice) and MC57-TyrHHD (grown in AOTA
mice [nonself]) were cocultured with 2C, pmel,
AFH (nonself), or FH (self) TCR-transgenic T cells.
Stromal cells from the various tumors were
compared to cultured cancer cells expressing the
same antigen. Supernatants were harvested after
24 hr of coculture and amounts of IFN-g and
TNF-a measured by ELISA. Data are shown as
percent of maximal cytokine secretion (anti-CD3
and anti-CD28 antibody stimulation, defined as
100%). For TNF-a, cytokine secretion by stromal
cells without T cells was subtracted to obtain
specific TNF-a secretion by T cells (443–975 pg/ml
by 1 3 105 cells cultured in 200 ml for 24 hr,
depending on experiment). Unstimulated T cells
served as negative control (below 0.7% for all re-
sponders, not shown). Data shown are combined
from two experiments and are representative for
four independent experiments.
See also Figure S4.
The asterisk indicates experiments were not done.
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colleagues demonstrated in vitro that the magnitude of T cell ac-
tivity against peptide/MHC was influenced more by peptide
binding to MHC than by binding of TCR to peptide/MHC,
especially for higher affinity TCRs (Bowerman et al., 2009).
Finally, T cells expressing the 2C TCR, even when targeting a
peptide/MHC complex with a 30-fold higher affinity, could not
prevent relapse in the absence of cross-presentation. Using
2C T cells to treat MC57-SIY and MC57-Ld tumors, SIY-
expressing tumors were rejected (Figure 2B; Spiotto et al.,
2004; affinity of 2C TCR for SIY-Kb [KD = 30 mM]), while MC57-
Ld cancer cells grew out as ALV (Spiotto et al., 2004; affinity of
2C for QL9- and p2Ca-Ld [KDz 1 mM]; Corr et al., 1994; Garcia
et al., 1997; Holler and Kranz, 2003). In contrast to SIY, QL9- and
p2Ca-Ld, recognized by 2C as alloantigens, cannot be cross-
presented, as the entire peptide/MHC complex would need to
be taken up by the stromal cells and then be re-presented on
their surface.
While we did not study the influence of several TCRs with
different affinities to one (same) peptide MHC complex, the influ-
ence of one TCR (pmel) on tumors expressing three peptides
with different affinities for MHC was studied here. The affinities
of the pmel TCR for the three peptide/MHC complexes studied,
mgp10025, EGP, and hgp10025 binding D
b, are not known;
however, alanine scans of murine and human gp10025 suggest
similar affinities, since the first three amino acids, which harbor
the only differences between the three peptides, do not522 Cancer Cell 23, 516–526, April 15, 2013 ª2013 Elsevier Inc.contribute to the binding of the peptide/
MHC complex to the TCR (but are impor-
tant for the binding of the peptides toMHC; Overwijk et al., 1998). Also, structural studies of these
peptides (van Stipdonk et al., 2009) in complexes with Db indi-
cate that the two positions that influenced binding to Db (p2
and p3) are both pointing down into the MHC pocket. In fact,
the authors did not see significant differences in any of the
exposed regions of the peptides, which would be in contact
with the TCR. Nevertheless, only cancer cells expressing the
peptidewith the highest affinity for Db (hgp10025) were effectively
killed in vivo, tumors expressing the other peptides relapsed be-
ing antigen positive. As none of the three peptides supported
complete tumor eradication, we further analyzed their affinity
for MHC in detail, which has given us insight into the importance
of the stability of peptide-MHC interactions. In the original
description of EGP (van Stipdonk et al., 2009), two different
RMA-S cell-based assays were employed to determine the rela-
tive affinity of EGP for Db compared to the murine gp100 peptide
(murine gp100 peptide [25–33] EGSRNQDWL [‘‘EGS’’]) and hu-
man gp100 peptide ‘‘KVP’’). These assays were: first, a binding
assay that measured cell surface Db levels as a function of pep-
tide concentration; in this assay, EGPwas almost 100-fold better
than hgp10025 (KVP) and 1,000-fold better thanmgp10025 (EGS).
Second, a stabilization assay measured the cell surface lifetimes
of the peptide/Db complexes. In this stabilization assay, EGP and
hgp10025 (KVP) showed similar lifetimes, whereas mgp10025
(EGS) had a considerable shorter lifetime (i.e., the complex
was less stable). Consistent with their results, we observed a
50-fold increased affinity of EGP over mgp10025, and this affinity
Figure 6. Death of Stromal Cells in T Cell-Treated SIY- and Tyr369-Expressing Tumors
MC57-SIY, MC57-TyrHHD, MC57-hgp100, andMC57-mgp100 tumors were treated with 2C, AFH (nonself) or pmel T cells, respectively. Five days after adoptive
transfer, single cell suspensions were generated from treated and untreated tumors and analyzed by flow cytometry. Histograms show CD11b+ T cells stained
with propidium iodide (PI) to identify cell death. Numbers indicate the percentage of dead cells among CD11b+ cells. Data are representative for four independent
experiments, with single mice per group.
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respectively). We used a cell-free competition-binding assay,
which is influenced by on- and off-rates (giving an approximation
of the dissociation constant [KD]). Taken together, EGP demon-
strated similar MHC stabilization compared to hgp10025 (van
Stipdonk et al., 2009). Indeed, like hgp10025, the affinity of
EGP for Db was insufficient to allow for tumor eradication.
Heteroclitic peptides can induce strong T cell responses
that include TCRs with high affinities (Gold et al., 2003; van
Stipdonk et al., 2009). However, these T cells will not be able
to eradicate tumors if the targeted tumor antigen has low affin-
ity for its presenting MHC. An example is a recent clinical trial
that showed no improvement of antimelanoma effects by addi-
tion of vaccinations with heteroclitic gp100 peptides to the
immune stimulating anti-cytotoxic T-lymphocyte antigen
(CTLA) 4 antibody (Hodi et al., 2010). The affinities of the corre-
sponding natural peptides are gp100209: 83–172 nM and
gp100280: 94–455 nM (Kawakami et al., 1995; Parkhurst et al.,
1996; Tsai et al., 1997).
Since our data show that high affinity of peptide for MHC re-
sults in tumor eradication along with strong stimulation of
T cells to secrete cytokines, future studies should concentrate
on targeting peptides that have high affinities for presenting
MHC class I. There are several algorithms that are constantly
being improved to give a fairly reliable prediction of peptide affin-
ities for MHC (e.g., Immune Epitope Database Analysis
Resource). Nevertheless, the predicted affinities of the peptides
show 2- to 20-fold differences when compared to the measured
affinities (as analyzed here for SIY and OVA257, respectively).
While the affinities of peptides for MHC can be accurately
measured in standardized cell-free assays, natural processing
and presentation of these putative peptides needs also to be
confirmed before selecting a peptide as a therapeutic target
(Popovic et al., 2011). Together, it should be possible to identify
optimal targets for T cell therapies when analysis of peptide-
MHC affinity is included.EXPERIMENTAL PROCEDURES
Cell Lines
Phoenix-ampho (Fujita et al., 1992) cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) (Mediatech, Manassas, VA), 10% nonheat inacti-
vated fetal calf serum (FCS) (Sigma-Aldrich, St. Louis, MO) at 37C in a 5%
CO2 humidified incubator. Cancer cells lines were cultured in DMEM, 5%
FCS (Gemini Bio-Products, West Sacramento, CA) at 37C in a 10% CO2
dry incubator. 8101 originated in a UV-treated C57BL/6 and has been
described (Dubey et al., 1997; Schreiber et al., 2001). P. Ohashi (University
of Toronto, Toronto, Ontario, Canada), with permission of H. Hengartner
(University Hospital Zurich, Zurich, Switzerland), provided the MC57G
methylcholanthrene-induced, C57BL/6-derived fibrosarcoma (MC57). Its
transfectant MC57-SIY-1 (MC57-SIY) has been described previously (Spiotto
et al., 2002). The new cell lines 8101- and MC57-hgp100, 8101- and MC57-
mgp100, 8101-SIY, MC57-EGP, andMC57-OVAwere generated by transduc-
tions of 8101 or MC57 with the Moloney murine leukemia virus-derived retro-
viral vector MFG expressing peptide-EGFP fusion genes (see Supplemental
Experimental Procedures for details on retroviral vectors and transductions).
MC57-mgp100/SIY was derived from MC57 by subsequent transduction
with MFG-(SIY)3-Cerulean and MFG-mgp100-EGFP. MC57-TyrHHD was ob-
tained by sequential transductions with MFG-Tyr-EGFP and MP71-HHD, en-
coding a fusion protein of a HLA-A2/Dd chimera and human b2m (Pascolo
et al., 1997).Mice
A list of the pairs of mice used as hosts of tumors and donors of T cells can be
found in Table 1. OVA257-K
b-specific TCR-transgenic OT-I mice were provided
by M. Mescher (University of Minnesota, Twin Cities, MN), the SIY-Kb-specific
TCR-transgenic 2Cmice were provided by J. Chen (Massachusetts Institute of
Technology, Cambridge, MA), and the human andmurine gp10025-D
b-specific
pmel-1 (referred to as pmel) were provided byN. Restifo (National Cancer Insti-
tute, Bethesda, MD) (Overwijk et al., 2003). Other TCR-transgenic mice used in
this study are the murine Tyr369-A2-specific AFH mouse (Nichols et al., 2007),
which is also AAD-transgenic (HLA-A2 and Db chimera; Newberg et al., 1996)
and albino (Tyr-deficient; Colella et al., 2000). It is important to note that the FH
TCR used for targeting the self-peptide mTyr369 has been derived in a nonself
setting. The TCR was obtained from a Tyr-deficient albino mouse (Nichols
et al., 2007), while the mouse from which pmel was obtained expressed
mgp10025 (Overwijk et al., 2003). This does not imply that the pmel TCR
specific for mgp10025 is of lower affinity but rather that TCRs with a certainCancer Cell 23, 516–526, April 15, 2013 ª2013 Elsevier Inc. 523
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expressed (FH) or of low affinity for MHC (pmel). The Tyr-positive, Tyr369-A2-
specific, AAD-transgenic FH mice were generated by crossing AFH to
C57BL/6J (The Jackson Laboratory, Bar Harbor, ME) and selecting black
(Tyr+) mice. The OT-I-, Thy1.1-, and AAD-transgenic strains AOTA (albino,
Tyr) and OTA (Tyr+) were obtained by crossing ATA (Nichols et al., 2007) to
OT-I/Thy1.1 (Thy1a; provided by T. Gajewski, The University of Chicago, Chi-
cago, IL) and selecting for mice with white or black fur color, respectively. All
colonies, including Rag1/ (B6.129S7-Rag1tm1Mom/J, The Jackson Labora-
tory), were maintained at the University of Chicago facilities. The Institutional
Animal Care and Use Committee at the University of Chicago approved all an-
imal experiments, and all experiments were performed to conform to the rele-
vant regulatory standards.
Peptides
The peptides EGP (EGPRNQDWL), hgp10025 (KVPRNQDWL), mgp10025
(EGSRNQDWL), OVA257 (SIINFEKL), SIY (SIYRYYGL), and Tyr369
(FMDGTMSQV) were made by solid-phase peptide synthesis using standard
9-fluorenylmethoxycarbonyl chemistry (see Supplemental Experimental
Procedures for details).
T Cell Cultures
NH4Cl
treated splenocytes were cultured at 4 3 106 cells/ml, 3 ml per well
of a 6-well plate in Roswell Park Memorial Institute medium (RPMI), 10%
FCS (Sigma-Aldrich), 2 mM glutamine, 50 mM b-mercaptoethanol, 1 mM
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Hepes), 1 mM sodium
pyruvate, 1X nonessential amino acids, 100 U/ml penicillin, 100 mg/ml strepto-
mycin, and 50 mg/ml gentamicin (all GIBCO/Invitrogen, Carlsbad, CA). T cells
were activated with 1 mg/ml anti-CD3 (145-2C11) and anti-CD28 (37.51, both
eBioscience, San Diego, CA) for killing assays in vitro or 1 mMcognate peptide:
SIY for 2C, Tyr369 for AFH and FH, OVA257 for OT-I, and hgp10025 for pmel.
Activated T cells were used for adoptive transfer after 3 days and for assays
in vitro after 4 days of culture.
Cytotoxicity Assay
Cell-mediated lysis of target cells by activated T cells was determined by
standard 4.5 hr 51Cr-release assay. Briefly, target cells were labeled for 1 hr
with 100 mCi 51Cr (Perkin Elmer, Waltham,MA) and incubated with T cells using
E:T ratios from 50:1 to 1.3:1 using 53 103 target cells. The 51Cr-released was
measured using a gamma counter (Titertek, Huntsville, AL). The percentage of
specific lysis was calculated as: % specific lysis = ([experimental release 
spontaneous release]/[maximum release  spontaneous release]) 3 100.
Tumor Challenge and Treatment
Cultured cancer cells were trypsinized and washed with PBS. Cancer cells in
suspension (MC57: 2 3 106/200 ml, 8101: 5–10 3 106/200 ml) were injected
subcutaneously onto the shaved back of mice. Tumor volumes were
measured along three orthogonal axes (a, b, and c) every 3 to 4 days and tumor
volume calculated as abc/2. MC57 tumors were treated after at least 14 days,
when tumors reached approximately 500mm3; 8101 tumors were treated after
at least 5 weeks, when tumors reached approximately 300 mm3. Mice were
treated with 3 day activated T cells, one spleen per recipient. We injected
5.5 ± 1.3 3 107 activated 2C T cells, 5.3 ± 2.4 3 107 activated FH T cells,
and 6.9 ± 2.2 3 107 activated pmel T cells (numbers were derived from six
independent experiments). 8101 tumors were treated with cells from half
a spleen only and with naive T cells in some of the experiments (see
Table S2). T cell suspensions were injected into the recipient via the retro
orbital plexus in two doses of 150 ml. For tumor protection, T cells were injected
on the day of tumor challenge or 3 days later, as indicated.
Isolation of Stromal and Cancer Cells from Tumors
Two-week-old, untreated tumors were used for functional analysis; tumors of
mice treated with T cells 4 or 5 days prior were used for flow cytometric anal-
ysis of T cells and stromal death, respectively. Tumors were surgically excised
and single cell suspensions generated by enzymatic digestion (see Supple-
mental Experimental Procedures). For stromal cross-presentation, CD11b+
cells were enriched using magnetic beads (Dynabeads FlowComp Flexi524 Cancer Cell 23, 516–526, April 15, 2013 ª2013 Elsevier Inc.[Invitrogen Dynal, Oslo, Norway] and anti-CD11b antibody [M1/70, BD
Bioscience, Franklin Lakes, NJ]).
To analyze antigen loss, relapsed tumors were surgically excised under ster-
ile conditions and placed in DMEM on ice. Tumors were minced to 1 to 2 mm
pieces and seeded in DMEM, 10% FCS, 100 U/ml penicillin, 100 mg/ml strep-
tomycin, 50 mg/ml gentamicin, and 50 mg/ml nystatin. Cells and fragments in
the flask were not moved for the initial three days and then cultured normally.
Cytokine Release Assay
T cells activated in vitro for 4 days were incubated with cancer cells cultured
in vitro or tumor stromal cells obtained ex vivo. For 24 hr, 1 3 105 responders
were cultured with 1 3 105 stimulators per well of a 96-well U-bottom plate.
Wells coated with 1 mg/ml of anti-CD3 (145-2C11) and anti-CD28 (37.51,
eBioscience) served as positive controls andmaximal stimulation. All superna-
tants were removed and tested for IFN-g and TNF-a using ELISA Kits (‘‘Femto-
HS’’ High Sensitivity, eBioscience), according to the manufacturer’s protocol.
Flow Cytometry
Cells were stained using directly labeled antibodies (see Supplemental Exper-
imental Procedures). Flow cytometry data were acquired on FACSCalibur or
FACSCanto machines (BD), and data were analyzed using FlowJo (Tree
Star, Ashland, OR) software. Cell sorting was performed using FACSAria
(BD) orMoFlo-HTS (Beckman Coulter, Brea, CA) at the FlowCytometry Facility
of The University of Chicago.
MHC Peptide-Binding Assays
MHC purification and quantitative assays to measure the binding affinity of
peptides to purified H2-Kb, H2-Db, and HLA-A*0201 molecules were per-
formed as previously described (Assarsson et al., 2007; Sidney et al., 2001;
see Supplemental Experimental Procedures for details). Under the conditions
used, where [label] < [MHC] and IC50R (MHC), the measured IC50 values are
reasonable approximations of the true KD values.
Statistical Analysis
Results of treatment of small groups of mice were analyzed using the
two-tailed probability calculated by the Fisher’s exact probability test (p %
0.05 is considered significant, p% 0.01 highly significant).
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.ccr.2013.03.018.
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